MedTrace Logo

Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection

NCT07228702 · Status: ENROLLING_BY_INVITATION · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2025-11-17

No results posted yet for this study

Summary

This study aims to use mycobacteriophage therapy, using identified in-vitro effective Mycobacteriophage Muddy\_HRMN0052, along with combination conventional antimycobacterial therapy for their NTM pulmonary disease with Mycobacterium abscessus with goal to reduce infection burden and improve pulmonary disease

Conditions

  • Non-Tuberculous Mycobacterial (NTM) Pneumonia
  • Mycobacterium Abscessus Infection

Interventions

BIOLOGICAL

Mycobacteriophage Muddy_HRMN0052

In-vitro effective Mycobacteriophage Muddy\_HRMN0052 against specific strain of Mycobacterium abscessus ssp abscessuss

DRUG

Amikacin Injection

Amikacin 1000mg IV 3x/wk

DRUG

Clofazimine

Clofazimine 100mg PO OD

DRUG

Bedaquiline (B)

Bedaquiline 400mg PO OD x 2 weeks then 200mg PO 3x/wk (Alternate agent if toxicity/intolerance to amikacin or clofazimine to ensure on 2 antibiotics throughout)

DRUG

Linezolid (LZD)

Linezolid 600mg PO OD (dose reduce to 600mg PO 3x/wk if adverse effects)(Alternate agent if toxicity/intolerance to amikacin or clofazimine to ensure on 2 antibiotics throughout)

DRUG

Sulfamethoxazole/Trimethoprim

Sulfamethoxazole/Trimethoprim 800/160mg PO BID (Alternate agent if toxicity/intolerance to amikacin or clofazimine to ensure on 2 antibiotics throughout)

Sponsors & Collaborators

  • Vancouver Coastal Health

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-30
Primary Completion
2027-10-31
Completion
2027-10-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07228702 on ClinicalTrials.gov